4,573
Views
61
CrossRef citations to date
0
Altmetric
Original Article

Development and in vitro evaluation of an oral SEDDS for desmopressin

, , , , &
Pages 2074-2083 | Received 06 Nov 2015, Accepted 13 Jan 2016, Published online: 29 Feb 2016

References

  • Bandivadekar M, Pancholi S, Kaul-Ghanekar R, et al. (2013). Single non-ionic surfactant based self-nanoemulsifying drug delivery systems: formulation, characterization, cytotoxicity and permeability enhancement study. Drug Dev Ind Pharm 39:696–703
  • Belhadj Z, Zhang S, Zhang W, Junlin W. (2013). Formulation development and bioavailability evaluation of a Self-nanoemulsifying Drug Delivery System (SNEDDS) of atorvastatin calcium. Int J Pharm 29:2051–5782
  • Choi SH, Park TG. (2000). Hydrophobic ion pair formation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres. Int J Pharm 203:193–202
  • Christiansen ML, Holm R, Kristensen J, et al. (2014). Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano Emulsifying Drug Delivery System (SNEDDS). Eur J Pharm Sci 57:164–72
  • Christophersen PC, Zhang L, Müllertz A, et al. (2014). Solid lipid particles for oral delivery of peptide and protein drugs II–the digestion of trilaurin protects desmopressin from proteolytic degradation. Pharm Res 31:2420–8
  • Fatouros DG, Deen GR, Arleth L, et al. (2007). Structural development of self nano emulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle X-ray scattering. Pharm Res 24:1844–53
  • Fosgerau K, Hoffmann T. (2015). Peptide therapeutics: current status and future directions. Drug Discov Today 20:122–8
  • Fredholt K, Østergaard J, Savolainen J, Friis GJ. (1999). α-Chymotrypsin-catalyzed degradation of desmopressin (dDAVP): influence of pH, concentration and various cyclodextrins. Int J Pharm 178:223–9
  • Friedl H, Dünnhaupt S, Hintzen F, et al. (2013). Development and evaluation of a novel mucus diffusion test system approved by self‐nanoemulsifying drug delivery systems. J Pharm Sci 102:4406–13
  • Hintzen F, Perera G, Hauptstein S, et al. (2014). In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin. Int J Pharm 472:20–6
  • Ilan E, Amselem S, Weisspapir M, et al. (1996). Improved oral delivery of desmopressin via a novel vehicle: mucoadhesive submicron emulsion. Pharm Res 13:1083–7
  • Jannin V, Chevrier S, Michenaud M, et al. (2015). Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity. Int J Pharm 495:385–92
  • Kahns AH, Buur A, Bundgaard H. (1993). Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (dDAVP). Pharm Res 10:68–74
  • Karamanidou T, Karidi K, Bourganis V, et al. (2015). Effective incorporation of insulin in mucus permeating self-nanoemulsifying drug delivery systems. Eur J Pharm Biopharm 97:223--9
  • Leonaviciute G, Bernkop-Schnürch A. (2015). Self-emulsifying drug delivery systems in oral (poly) peptide drug delivery. Expert Opin Drug Deliv 12:1703–16
  • Mahjub R, Dorkoosh FA, Rafiee-Tehrani M, Bernkop Schnürch A. (2015). Oral self-nanoemulsifying peptide drug delivery systems: impact of lipase on drug release. J Microencapsul 32:401–7
  • Matsui K, Kimura T, Ota K, et al. (1985). Resistance of 1-deamino-(8-D-arginine)-vasopressin to in vitro degradation as compared with arginine vasopressin. Endocrinol Jpn 32:547–57
  • Meyer JD, Manning MC. (1998). Hydrophobic ion pairing: altering the solubility properties of biomolecules. Pharm Res 15:188–93
  • Müllertz A, Ogbonna A, Ren S, Rades T. (2010). New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 62:1622–36
  • Palamakula A, Khan MA. (2004). Evaluation of cytotoxicity of oils used in coenzyme Q10 Self-emulsifying Drug Delivery Systems (SEDDS). Int J Pharm 273:63–73
  • Partenhauser A, Laffleur F, Rohrer J, Bernkop-Schnürch A. (2015). Thiolated silicone oil: synthesis, gelling and mucoadhesive properties. Acta Biomater 16:169–77
  • Pouton CW. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29:278–87
  • Pouton CW, Porter CJH. (2008). Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev 60:625–37
  • Rao SVR, Shao J. (2008). Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: I. Formulation development. Int J Pharm 362:2–9
  • Schmitz T, Huck CW, Bernkop-Schnürch A. (2006). Characterisation of the thiol-disulphide chemistry of desmopressin by LC, mu-LC, LC-ESI-MS and Maldi-Tof. Amino Acids 30:35–42
  • Shen H, Zhong M. (2006). Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol 58:1183–91
  • Shen WC. (2003). Oral peptide and protein delivery: unfulfilled promises? Drug Discov Today 8:607–8
  • Thomas N, Müllertz A, Graf A, Rades T. (2012). Influence of lipid composition and drug load on the in vitro performance of self‐nanoemulsifying drug delivery systems. J Pharm Sci 101:1721–31
  • Wang J, Shen D, Shen WC. (1999). Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity. Pharm Res 16:1674–9
  • Wang J, Wu D, Shen WC. (2002). Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates. Pharm Res 19:609–14
  • Wang J, Yadav V, Smart AL, et al. (2015). Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol Pharm 12:966–73
  • Zhao FK, Chuang LF, Israel M, Chuang RY. (1989). Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C. Biochem Biophys Res Commun 159:1359–67
  • Zupančič O, Partenhauser A, Lam HT, et al. (2016). Development and in vitro characterisation of an oral self-emulsifying delivery system for daptomycin. Eur J Pharm Sci 81:129--36

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.